The onboarding and training of our expanded U.S. field sales organization is underway, and we believe we will be fully prepared for the commercial launch of the soft tissue repair indication following expected FDA approval in June.
Further, we are on track to submit our PMA supplement to the FDA for RECELL GO by the end of the second quarter.
We believe RECELL GO is a critical component of our platform and has the potential to significantly accelerate our growth trajectory.”
Future Milestones • Expect FDA approval for soft tissue repair indication in June 2023 followed by the commercial launch on July 1, 2023
Anticipate FDA submission of RECELL GO by June 30, 2023
Ann: Quarterly Financial Report Form 10-Q, page-2
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.67 |
Change
-0.060(2.20%) |
Mkt cap ! $160.7M | |||
| Open | High | Low | Value | Volume |
| $2.72 | $2.73 | $2.65 | $791.0K | 293.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4333 | $2.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.68 | 9529 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.66 |
Change
-0.060 ( 3.24 %) |
||||
| Open | High | Low | Volume | ||
| $2.71 | $2.73 | $2.65 | 25459 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| AVH (ASX) Chart |